Delmitide (RDP58) 是一种 具有有效的抗炎活性的 d-异构体十肽,具有口服活性。Delmitide 抑制 TNF-α、IFN-γ 和白细胞介素 (IL)-12 的产生,并上调血红素加氧酶 1 的活性。Delmitide 可用于溃疡性结肠炎的研究。
生物活性 | Delmitide (RDP58) is an orally active d-isomer decapeptide with potentanti-inflammatoryactivity. Delmitide inhibits production of TNF-α,IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis[1][2]. |
体内研究 (In Vivo) | Delmitide (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo[2]. Delmitide (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice[2].
Animal Model: | BALB/c mice (female, 9-10-week)[2] | Dosage: | 2.5, 5, 10 mg/kg or 0.2 mL, 10 mg/kg | Administration: | Oral, daily | Result: | Reduced the incidence of diarrhea and attenuated CPT-11-associated GI toxicity and mortality in a dose-dependent manner. Had protective effect against chemotherapy-induced GI side-effects and reduced CPT-11-induced overexpression of TNF-α, IFN-γ, and IL-12 in vivo. Preserved the intestinal mucosa morphology by maintaining villus and crypt structure and inhibited TNF-α-mediated apoptosis in the crypt compartment, thereby protecting intestinal mucosa integrity in mice. Protected mice from CPT-11-induced GI toxicity and mortality and enhanced animal survival in tumor-bearing mice. Significantly reduced the incidence and overall tumor burden in a spontaneously metastatic model. |
|
分子量 | |
Formula | |
CAS 号 | |
Sequence Shortening | D(R-Nle-Nle-Nle-R-Nle-Nle-Nle-GY-NH2) |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |